PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Gross Profit: MAD424.7 Mil (TTM As of Dec. 2025)

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Gross Profit?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO 88 Gross Profit is MAD424.7 Mil as of Dec. 2025. GuruFocus rates CAS:PRO with a GF Score™ of 88/100 and a GF Value™ of MAD1,334.52 (Fairly Valued). The stock has 6 warning signs investors should review.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's gross profit for the six months ended in Dec. 2025 was MAD217.8 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was MAD424.7 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's gross profit for the six months ended in Dec. 2025 was MAD217.8 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Revenue for the six months ended in Dec. 2025 was MAD515.5 Mil. Therefore, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Margin % for the quarter that ended in Dec. 2025 was 42.24%.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM had a gross margin of 42.24% for the quarter that ended in Dec. 2025 => Durable competitive advantage

During the past 10 years, the highest Gross Margin % of PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM was 57.95%. The lowest was 43.35%. And the median was 52.42%.

Warning Sign:

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM gross margin has been in long-term decline. The average rate of decline per year is -4.7%.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM had a gross margin of 42.24% for the quarter that ended in Dec. 2025 => Durable competitive advantage

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Gross Profit Related Terms

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Gross Profit Historical Data

* Premium members only.

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Gross Profit Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Gross Profit

Get a 7-Day Free Trial

330.53

372.47

359.24

389.89

424.75

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Gross Profit	Get a 7-Day Free Trial															178.07	185.07	204.82	206.99	217.76

CAS:PRO vs ZTS, UTHR, VTRS: Gross Profit Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Gross Profit vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit distribution charts can be found below:

* The bar in red indicates where PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit falls into.

Save Embed

88GF Score

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO

Gross Profit is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit for the fiscal year that ended in Dec. 2025 is calculated as

Gross Profit (A: Dec. 2025 )	=	Revenue	-	Cost of Goods Sold
	=	979.734	-	554.985
	=	424.7

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit for the quarter that ended in Dec. 2025 is calculated as

Gross Profit (Q: Dec. 2025 )	=	Revenue	-	Cost of Goods Sold
	=	515.519	-	297.757
	=	217.8

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD424.7 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Margin % for the quarter that ended in Dec. 2025 is calculated as

Gross Margin % (Q: Dec. 2025 )	=	Gross Profit (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	217.8	/	515.519
	=	42.24 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Profit →

What does a Gross Profit of MAD424.7 Mil mean?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Gross Profit of MAD424.7 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit too high?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Gross Profit is MAD424.7 Mil. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit compare to ZTS and UTHR?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Gross Profit of MAD424.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Gross Profit for a Drug Manufacturers company?

A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Gross Profit mean?

A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Gross Profit is MAD424.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,334.52, compared to a current price of MAD1,269.00 — trading 4.9% below its estimated fair value. The current Gross Profit is MAD424.7 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Gross Profit calculated?

Gross Profit is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Gross Profit is MAD424.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be undervalued. The current stock price of MAD1,269.00 is trading 4.9% below its estimated GF Value™ of MAD1,334.52. GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.

Key valuation signals for CAS:PRO:

Gross Profit: MAD424.7 Mil
GF Value™: MAD1,334.52 vs. price of MAD1,269.00 (4.9% below fair value)
GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506 XPAR:IPN TSE:4507 TPE:6446

Address Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400

Website http://www.promopharm.co.ma

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.

88GF Score

Get the complete analysis for CAS:PRO

Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD1,269.00

Price

MAD1,334.52

GF Value

View CAS:PRO Analysis

See Gross Profit data for all stocks →